The case records of 262 patients who received 131l therapy during a 6-year period were analysed retrospectively. These included seventy-eight patients who received more than one therapeutic dose.
The major indication for 131I therapy was thyrotoxicosis occurring in patients aged 40 years and over. The racial incidence in this series is striking.
The effects on thyroid function of two low-dose schedules (4 mCi and 6 mCi) were compared. The major complication encountered was hypothyroidism. 4 mCi appears to be as effective as 6 mCi with the added advantage of producing less hypothyroidism. RADIOACTIVE iodine is now an integral part of the therapy of thyrotoxicosis in selected cases. Since the earlier reports of the work of Balls et al. (1955) , Beierwaltes & Johnson (1956) and Chapman & Maloof (1955) , much data has accumulated concerning the indications for, dosage of and complications following 131I therapy.
Discrepancies between the many reports available concerning the various factors involved with 131I administration has prompted us to evaluate our experience at Groote Schuur Hospital over a 6-year period (January 1965 -March 1971 
Results
The age distribution of the 262 patients is shown in Fig. 1 . The bulk of the patients fell between the ages of 40 and 59. Of this group thirty-three (12-2%) were males and 229 (87-8%) were females.
Our study confirms the belief that thyrotoxicosis is rare in the African (Bantu) ( Table 1) .
The main indications for 131I therapy were (a) age alone; (b) clinically important cardiac disease (including thyrocardiac and rheumatic heart disease); (c) recurrence after surgery; (d) failure of medical treatment, i.e. antithyroid and/or beta-blocking agents administered for not less than 6 months; and (e) a miscellaneous group including, amongst Radio-iodine therapy for thyrotoxicosis Fig. 2 , in more than half the patients, age was the sole indication for 131I. Although certain patients fulfilled more than one criterion only the major indication is tabulated in this figure. (Fig. 3) . Table 3 reflects the number of doses administered to the seventy-eight patients who needed retreatment. The majority required only two doses for control. (Fig. 4) .
Discussion
The efficacy and simplicity of radio-iodine administration with the incidental benefits of out-patient treatment, has made this the therapy of choice in a large number of clinical centres. However, the 30-year period during which it has been available is barely sufficient to evaluate its particular hazards.
In our series, the commonest indication for 131I therapy was the age of presentation. In the selection of patients the policy of our clinic is to treat only those 40 years and over. (Dancaster, 1970; Patel, 1962; Taylor, 1968) . This phenomenon has been attributed to a possible immunological abnormality in these patients (Dancaster, 1970; Taylor, 1968) , and this was confirmed by the work of McGill (1971) .
Treatment of thyrotoxicosis with radio-iodine has been marred by the fact that hypothyroidism appears to be inevitable in a certain proportion of patients so treated. Attention has thus focussed on finding a dose that would exploit the advantages of this therapy while decreasing the risk of hypothyroidism. To this end low 131I dosage has been recommended (Green & Wilson, 1964; Hagen, Ouellette & Chapman, 1961) . However, the use of a low radiation dose has resulted in a higher proportion of patients who remained hyperthyroid after treatment (Smith & Wilson, 1967 (Hamburger et al., 1964) . In our series, fifteen cases had cardiac disease severe enough to warrant a dose in excess of 6 mCi (see Table 3 ).
Various workers (Seed & Jaffe, 1953; McGirr, Thompson & Murray, 1964 ; Sheline & Miller, 1959) have shown that toxic autonomous nodular goitres and toxic multinodular goitres require a larger initial dose for adequate control. This was seen in our two patients with multinodular toxic goitres who had each received 46 mCi 131I. Furthermore, the irregular distribution of radio-iodine in a toxic multinodular goitre may protect the patient against hypothyroidism when a single dose is given (Hamburger, Kadian & Rossin, 1967) .
Gland size is used in several units as one of the indices of dose requirement, although it is well known that the determination of gland volume by palpation is subject to error and that the larger the gland the less accurate the estimate. A large thyroid gland appears to require larger doses of radio-iodine for restitution of euthyroidism. Goolden & Fraser (1969) have advocated a sliding scale in which the dose level was determined by gland size.
Prior to 1968, 6 mCi of 131I was the standard dose administered to all our thyrotoxic patients requiring this form of therapy. Since then, 4 mCi has been employed irrespective of gland size and nodularity. Adequate documentation of gland characteristics was not always available and its relationship to the dose administered could thus not be meaningfully interpreted in this retrospective study.
Despite the various manoeuvres employed to achieve optimal results, these often fall short because the radiation sensitivity of the particular gland, and the recognized tendency of radio-iodine to have a patchy distribution within the gland cannot be assessed clinically (Hagen, 1968) . Complications Table 4 lists the possible complications of radioiodine therapy.
Initial reactions
Within 10 days a local, usually mild, reaction may set in with swelling and tenderness of the thyroid gland. In addition, exacerbation of thyrotoxic symptoms may occur. Two of our patients were noted to develop aggravation of their clinical state within this period, one with impending thyroid crisis (see Table 5 ).
Thyroid storm or crisis under these circumstances is thought to be due to liberation of preformed, stored thyroid hormone from a radiation-damaged gland. Treatment with beta-blocking agents, iodide and steroids may be necessary.
Prophylactic depletion of intrathyroidal hormone by antithyroid drugs has been advocated in patients with severe cardiac decompensation prior to 131I therapy (Hamburger & Sukhamoy, 1968) . We have not employed this form of 'pretreatment' routinely in our cardiac patients, but have maintained them on diuretics, digoxin and, in selected cases, the beta- (Greig, 1965 (Chapman et al., 1954) . In this phase of temporary hypothyroidism substitution therapy should be withheld or used on a short-term basis for symptomatic cases until repeat tests are performed 3 months later. In our series the incidence of hypothyroidism includes both the temporary and permanent state. As expected this complications more common with 6 mCi.
Most patients become euthyroid within 6 months after receiving 131I. At this stage thyroid status should be re-assessed. Those patients who are still mildly toxic may be tided over with antithyroid medication. Those severely toxic may require further radio-iodine therapy. In this manner it is hoped to reduce the incidence of hypothyroidism to a minimum. In the majority of our retreated patients 6 months had elapsed before administration of the next dose.
Nodulation of the thyroid as a late complication of radio-iodine therapy was found in 8%/ of 177 young thyrotoxic patients reported in the literature (Hayek et al., 1970) .
The possible carcinogenic and genetic hazards have been mentioned previously.
Although overt hypoparathyroidism is a very rare complication of 131I therapy (Tighe, 1952; Eipe et al., 1968; Orme & Conolly, 1971) , Adams & Chalmers (1965) found that 10% of patients so treated were unable to restore serum calcium levels to normal following intravenous infusion of ethylene diaminetetracetic acid (EDTA). We have not Recurrence of hyperthyroidism once normal thyroid function has been maintained for 6 months, is extremely rare (Chapman & Maloof, 1955) . We have not encountered this in our series.
We conclude from our experience of 262 patients treated for thyrotoxicosis with either 4 mCi or 6 mCi of 1311, that 4 mCi is probably as effective as 6 mCi in achieving euthyroidism. The incidence of hypothyroidism appears to be less with the 4 mCi dose. A time period of 6 months is recommended before repeat administration.
